Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection
July 17, 2023 08:45 ET
|
Novan, Inc.
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15...
Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders
June 05, 2023 09:00 ET
|
Novan, Inc.
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of...
Novan Focuses Strategic Direction and Announces Restructuring
May 31, 2023 16:05 ET
|
Novan, Inc.
– Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum – – Process to explore a sale or out-license of commercial assets or other business...
Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 15, 2023 06:45 ET
|
Novan, Inc.
– Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) – – Strong prescription growth across three promoted products – – Company to host conference call...
Novan to Report First Quarter 2023 Financial Results on May 15, 2023
May 08, 2023 09:05 ET
|
Novan, Inc.
DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May...
Novan Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement¹
April 27, 2023 09:10 ET
|
Novan, Inc.
Published results from a National Psoriasis Foundation-fielded survey included responses from more than 400 patients across US1 Findings highlight impact on patient adherence of early onset of...
Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD
April 20, 2023 09:00 ET
|
Novan, Inc.
DURHAM, N.C., April 20, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host an Analyst and Investor Event: A Discussion of Molluscum’s...
Novan Reports Full Year 2022 Financial Results and Provides Corporate Update
March 30, 2023 06:30 ET
|
Novan, Inc.
– Berdazimer gel, 10.3% (SB206) assigned PDUFA goal date of January 5, 2024 – – Strong year-over-year prescription growth across three promoted products, RHOFADE, WYNZORA and MINOLIRA – – Company...
Novan to Report Full Year 2022 Financial Results on March 30, 2023
March 23, 2023 09:00 ET
|
Novan, Inc.
DURHAM, N.C., March 23, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2022 financial results on Thursday,...
Novan Announces Closing of $6.0 Million Registered Direct Offering
March 16, 2023 16:15 ET
|
Novan, Inc.
DURHAM, N.C., March 16, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the closing of the issuance and sale in the Company’s previously announced...